These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 15997923)

  • 1. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study.
    Stubblefield MD; Vahdat LT; Balmaceda CM; Troxel AB; Hesdorffer CS; Gooch CL
    Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):271-6. PubMed ID: 15997923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
    Papadopoulos KP; Egorin MJ; Huang M; Troxel AB; Kaufman E; Balmaceda CM; Vahdat LT; Hesdorffer CS
    Cancer Chemother Pharmacol; 2001; 47(1):45-50. PubMed ID: 11221961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
    Vahdat L; Papadopoulos K; Lange D; Leuin S; Kaufman E; Donovan D; Frederick D; Bagiella E; Tiersten A; Nichols G; Garrett T; Savage D; Antman K; Hesdorffer CS; Balmaceda C
    Clin Cancer Res; 2001 May; 7(5):1192-7. PubMed ID: 11350883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
    Openshaw H; Beamon K; Synold TW; Longmate J; Slatkin NE; Doroshow JH; Forman S; Margolin K; Morgan R; Shibata S; Somlo G
    Clin Cancer Res; 2004 Jan; 10(2):461-7. PubMed ID: 14760066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial.
    Ghoreishi Z; Esfahani A; Djazayeri A; Djalali M; Golestan B; Ayromlou H; Hashemzade S; Asghari Jafarabadi M; Montazeri V; Keshavarz SA; Darabi M
    BMC Cancer; 2012 Aug; 12():355. PubMed ID: 22894640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support.
    Schwartzberg LS; Weaver CH; Birch R; Giudice R; Sobong E; Schnell F; Kalman L; Buckner CD
    Am J Clin Oncol; 1999 Apr; 22(2):162-7. PubMed ID: 10199451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
    Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
    Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurosteroid 3α-androstanediol efficiently counteracts paclitaxel-induced peripheral neuropathy and painful symptoms.
    Meyer L; Patte-Mensah C; Taleb O; Mensah-Nyagan AG
    PLoS One; 2013; 8(11):e80915. PubMed ID: 24260511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
    Amara S
    Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery.
    Storey DJ; Colvin LA; Mackean MJ; Mitchell R; Fleetwood-Walker SM; Fallon MT
    J Pain Symptom Manage; 2010 Jun; 39(6):e2-4. PubMed ID: 20538177
    [No Abstract]   [Full Text] [Related]  

  • 14. Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings.
    Augusto C; Pietro M; Cinzia M; Sergio C; Sara C; Luca G; Scaioli V
    J Neurooncol; 2008 Jan; 86(1):89-99. PubMed ID: 17611715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
    Sánchez-Barroso L; Apellaniz-Ruiz M; Gutiérrez-Gutiérrez G; Santos M; Roldán-Romero JM; Curras M; Remacha L; Calsina B; Calvo I; Sereno M; Merino M; García-Donas J; Castelo B; Guerra E; Letón R; Montero-Conde C; Cascón A; Inglada-Pérez L; Robledo M; Rodríguez-Antona C
    Oncologist; 2019 Aug; 24(8):e784-e792. PubMed ID: 30470691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
    Davis ID; Kiers L; MacGregor L; Quinn M; Arezzo J; Green M; Rosenthal M; Chia M; Michael M; Bartley P; Harrison L; Daly M
    Clin Cancer Res; 2005 Mar; 11(5):1890-8. PubMed ID: 15756015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
    Vahdat LT; Balmaceda C; Papadopoulos K; Frederick D; Donovan D; Sharpe E; Kaufman E; Savage D; Tiersten A; Nichols G; Haythe J; Troxel A; Antman K; Hesdorffer CS
    Bone Marrow Transplant; 2002 Aug; 30(3):149-55. PubMed ID: 12189532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer.
    Postma TJ; Hoekman K; van Riel JM; Heimans JJ; Vermorken JB
    J Neurooncol; 1999; 45(3):241-6. PubMed ID: 10845395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.